

EXHIBIT 3

Confidential - Subject to Further Confidentiality Review

Page 1

IN THE UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF ILLINOIS

D.W.K., a minor, by MARY)	
KALETA and DANIEL KALETA,)	
individually as parents and)	
next friends of D.W.K.,)	
)	
C.P., a minor, and E.P., a)	
minor, by ROGER PYSZKOWSKI)	
and MINDY PYSZKOWSKI,)	Case No.
individually as parents and)	14-cv-847-NJR
next friends of C.P. and)	
E.P.,)	
)	
J.F., a minor, by MICHELLE)	
LEAL, individually as parent)	
and next friend of J.F.,)	
)	
Plaintiffs,)	
)	
vs.)	
)	
ABBOTT LABORATORIES, INC.,)	
)	
Defendant.)	

CONFIDENTIAL - SUBJECT TO FURTHER CONFIDENTIALITY REVIEW

VIDEOTAPED DEPOSITION OF:
JAMES EMBRESCIA, M.D.
DECEMBER 11, 2014
CHICAGO, ILLINOIS

REPORTED BY: MARIANNE NEE,
CSR, CRR, RDR

1 there was a recommendation for that.

2 BY MR. SAMPSON:

3 Q. So if you look at the second page,
4 Dr. Embrescia, under No. 4, No. 4 says develop
5 or -- "Discuss and develop a flowchart for the
6 treatment of adult epilepsies and co-morbid
7 conditions." Do you see that?

8 A. I do.

9 Q. The first bullet point says, "Not
10 use Depakote in female of childbearing years due
11 to teratogenicity potential," right?

12 A. Oh, yes. Okay, I see it. What page
13 are you --

14 Q. The second page.

15 A. Yes, I see it now.

16 Q. The first bullet point under No. 4.

17 A. Got it.

18 Q. This Abbott 2001 document reflects
19 that these consultants that were part of the
20 meeting, at least part of their position was,
21 "Not use Depakote in female of childbearing
22 years due to teratogenic potential," right?

23 MR. MacWILLIAMS: Objection; form and
24 foundation and scope.

Confidential - Subject to Further Confidentiality Review

Page 239

1 BY THE WITNESS:

2 A. I'm looking for the words
3 teratogenic potential. There it is, yes.
4 That's what the words say, yes.

5 BY MR. SAMPSON:

6 Q. Did the people who were assessing
7 Depakote's safety profile in the early 2000s
8 take into consideration the fact that Abbott's
9 neurology consultants had suggested that
10 Depakote not be used in females of childbearing
11 years due to its teratogenic potential?

12 MR. MacWILLIAMS: Objection; form,
13 foundation and scope.

14 BY THE WITNESS:

15 A. Again, to my knowledge -- I have no
16 knowledge of this document. I don't know where
17 it came from and I don't believe it was ever
18 discussed within the safety organization, so I
19 can't answer the question.

20 BY MR. SAMPSON:

21 Q. So you don't recall any discussion
22 about Abbott neurology consultants suggesting
23 that Depakote should not be used in females of
24 childbearing years in the early 2000 timeframe?

Confidential - Subject to Further Confidentiality Review

Page 240

1 MR. MacWILLIAMS: Objection; form,
2 foundation, scope and asked and answered.

3 BY THE WITNESS:

4 A. Again, as I said at the beginning of
5 this, I have no knowledge of Abbott neurology
6 consultants at all, so I can't answer any
7 question on that.

8 BY MR. SAMPSON:

9 Q. I'm handing you Exhibit 992.

10 A. Thank you.

11 (Exhibit 992 was marked for
12 identification.)

13 BY MR. SAMPSON:

14 Q. This is an article from the
15 publication Seizure in 2002. Do you see that?

16 A. I do.

17 Q. And the lead author is Mawer?

18 A. Yes, sir, it is.

19 Q. The title is, "Outcome of pregnancy
20 in women attending an outpatient epilepsy
21 clinic: adverse features associated with higher
22 doses of sodium valproate," right?

23 A. That is the title, yes.

24 Q. Sodium valproate is a form of

Confidential - Subject to Further Confidentiality Review

Page 372

1 indirectly in the outcome of this action.

2 I further certify that this certificate
3 applies to the original and certified
4 transcripts only. I assume no responsibility
5 for the accuracy of any reproduced copies not
6 made under my control or direction.

7 IN WITNESS WHEREOF, I do hereunto set
8 my hand at Chicago, Illinois, this 23rd day of
9 December, 2014.

10

11

12

13

Marianne Nee

Certified Shorthand Reporter

14

15

C.S.R. Certificate No. 84-2341

16

17

18

19

20

21

22

23

24